Advertisement
News
Subscribe to MDT Magazine News

Retired Aetna CEO exercised $50M in stock options

April 12, 2011 12:45 pm | by TOM MURPHY - AP Business Writer - Associated Press | Comments

Aetna's retired CEO Ronald Williams gave himself a lucrative farewell last year by exercising stock options worth more than $50 million.The 61-year-old executive also received a compensation package totaling $18.4 million from Aetna and heads into retirement with a pension valued at $9.5 million...

Investigational Drug May Reduce Involuntary Movements in People With Parkinson's Disease

April 12, 2011 12:36 pm | by Bio-Medicine.Org | Comments

HONOLULU, April 12, 2011 /PRNewswire-USNewswire/ -- Results of the first randomized, placebo-controlled long-term clinical trial show the investigational drug safinamide may reduce dyskinesia or involuntary movements in mid-to-late stage Parkinson's disease. The findings will be presented...

TOPICS:

Changing trends in hip fracture incidence around the world

April 12, 2011 11:42 am | by EurekAlert | Comments

(International Osteoporosis Foundation) A review by a scientific working group of the IOF shows that age-specific hip fracture rates have changed during recent decades -- decreasing in some countries or regions while increasing in others. The review examines some possible reasons...

TOPICS:
Advertisement

BioScale scales up with new MEMS sensor fab cleanrooms, HQ

April 12, 2011 11:41 am | by I-Micronews | Comments

BioScale Inc., a life science company that develops, manufactures, and promotes novel analytical tools enabling advancements in protein research, relocated its corporate headquarters to 4 Maguire Road in Lexington, MA.

Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin

April 12, 2011 11:36 am | by Bio-Medicine.Org | Comments

EAST HANOVER, N.J., April 12, 2011 /- Novartis Pharmaceuticals Corporation ("Novartis") announced today that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of Afinitor® (everolimus) tablets for the treatment of patients with...

TOPICS:

MSA Schedules First Quarter Earnings Webcast

April 12, 2011 11:35 am | by Bio-Medicine.Org | Comments

PITTSBURGH, April 12, 2011 /- MSA (NYSE: MSA ), the global leader in the development, manufacture and supply of products that protect people's health and safety, announced today that it will broadcast a first quarter 2011 earnings conference call live via the Internet on Thursday, April...

TOPICS:

Biotech and cystic fibrosis: A kid's view

April 12, 2011 10:42 am | by Mass High Tech: The Journal of New England Technology | Comments

The star of the show was an 8-year-old Red Sox fan from Dedham named Bobby Coughlin, not the 200 globe-trotting investors and accomplished life sciences executives who were both the attendees and speakers at the Boston Biotech Conference. He sat with his father, MassBio president and CEO...

Concert Pharmaceuticals names Roessel, Sabounjian to exec roles

April 12, 2011 10:42 am | by Mass High Tech: The Journal of New England Technology | Comments

Concert Pharmaceuticals Inc. has made two new executive appointments to grow its development work. Mark Roessel has been named vice president of regulatory affairs and quality assurance, while LuAnn Sabounjian has been appointed vice president of clinical operations.

Advertisement

Consumer thrift on health care could help insurers

April 12, 2011 9:45 am | by The Associated Press | Comments

Managed health care companies will likely report upbeat first-quarter financial results, as consumers continue to cut spending on medical visits in a recovering economy, according to a Wedbush analyst Tuesday.Several insurers benefited from that trend throughout the third and fourth quarters,...

Montana Medical Equipment Providers Back New Congressional Bill to Repeal Flawed Medicare Bidding Program

April 12, 2011 9:36 am | by Bio-Medicine.Org | Comments

HELENA, Mont., April 12, 2011 /PRNewswire-USNewswire/ -- The association representing Montana's providers of home medical equipment and services supports a new, bipartisan bill in Congress to repeal the controversial Medicare "competitive" bidding program for home medical equipment and...

TOPICS:

Perrigo Announces Conclusion of the FDA Re-Inspection

April 12, 2011 9:35 am | by Bio-Medicine.Org | Comments

ALLEGAN, Mich., April 12, 2011 /- Perrigo (Nasdaq: PRGO ; TASE) today announced that the Detroit Office of the Food and Drug Administration (FDA) has concluded its re-inspection of Perrigo's Allegan facility. The FDA has informed Perrigo that, effective immediately, the Company has an...

TOPICS:

Sanofi-aventis CEO Viebacher details strategy post-Genzyme buyout

April 12, 2011 8:40 am | by Mass High Tech: The Journal of New England Technology | Comments

Sanofi-aventis CEO Chris Viebacher outlined the research and development strategy that led to the purchase of Cambridge-based Genzyme Corp. for $20.1 billion and will lead the company to further expand its partnerships and acquisitions.

Top 30 MEMS Companies 2010: Big four capture a third of the total MEMS market

April 12, 2011 8:40 am | by I-Micronews | Comments

The MEMS industry had a great 25% growth year in 2010--but the four largest companies grew even faster, to increase their domination of Yole Développement's annual Top30 MEMS company ranking, and of the sector as a whole. These giants now account for some $2.9 billion of the sector's $8.6...

Allen Institute for Brain Science Announces First Comprehensive Gene Map of the Human Brain

April 12, 2011 8:37 am | by Bio-Medicine.Org | Comments

SEATTLE, April 12, 2011 /- The Allen Institute for Brain Science has released the world's first anatomically and genomically comprehensive human brain map, a previously unthinkable feat made possible through leading-edge technology and more than four years of rigorous studies and...

TOPICS:

Max Neeman International Completes Targeted Enrollment of 15,000 for Large Ph IV Study

April 12, 2011 8:37 am | by Bio-Medicine.Org | Comments

RESEARCH TRIANGLE PARK, N.C., April 12, 2011 /- Max Neeman meets enrollment and timeline of 15,000 for a large, Phase IV metabolic disorder trial across 1200 sites throughout India. As a leading Indian CRO, the company has completed multiple Phase IV studies for global sponsors with...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading